Syndax Pharmaceuticals, Inc. (SNDX): Price and Financial Metrics

Syndax Pharmaceuticals, Inc. (SNDX)

Today's Latest Price: $22.87 USD

0.26 (-1.12%)

Updated Nov 27 1:00pm

Add SNDX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SNDX Stock Summary

  • Syndax Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 9.45% of US listed stocks.
  • SNDX's price/sales ratio is 623.55; that's higher than the P/S ratio of 99.03% of US stocks.
  • With a year-over-year growth in debt of 1,948.95%, Syndax Pharmaceuticals Inc's debt growth rate surpasses 98.81% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Syndax Pharmaceuticals Inc are OTIC, KLDO, CKPT, QURE, and DCPH.
  • SNDX's SEC filings can be seen here. And to visit Syndax Pharmaceuticals Inc's official web site, go to

SNDX Stock Price Chart Interactive Chart >

Price chart for SNDX

SNDX Price/Volume Stats

Current price $22.87 52-week high $23.98
Prev. close $23.13 52-week low $6.32
Day low $22.57 Volume 658,842
Day high $23.40 Avg. volume 516,841
50-day MA $17.95 Dividend yield N/A
200-day MA $15.12 Market Cap 934.67M

Syndax Pharmaceuticals, Inc. (SNDX) Company Bio

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company was founded in 2005 and is based in Waltham, Massachusetts.

SNDX Latest News Stream

Event/Time News Detail
Loading, please wait...

SNDX Latest Social Stream

Loading social stream, please wait...

View Full SNDX Social Stream

Latest SNDX News From Around the Web

Below are the latest news stories about Syndax Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNDX as an investment opportunity.

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2020 Results - Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Melissa Forst - Senior Vice President, Argot Partners Briggs Morrison - Chief Executive Officer Daphne Karydas - Chief Financial Officer Conference Call Participants Chris Shibutani - Cowen & Company Shawn Egan - Citigroup Presentation...

SA Transcripts on Seeking Alpha | August 9, 2020

Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2020 financial results on Thursday, August 6, after the close of the U.S. financial markets.

Yahoo | July 30, 2020

Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Daphne Karydas as Chief Financial Officer, effective July 13, 2020. Ms. Karydas, who brings to Syndax nearly 20 years of financial experience in the biopharmaceutical industry, most recently served as Senior Vice President of Corporate Financial Planning & Analysis and Strategy at Allergan, where she oversaw the company's long-term financial and business strategy. She will succeed Richard P. Shea, who will be retiring from his role as Syndax's Chief Financial Officer.

Yahoo | July 7, 2020

Hedge Funds Have Never Been This Bullish On Syndax Pharmaceuticals, Inc. (SNDX)

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

Yahoo | June 23, 2020

Edited Transcript of SNDX earnings conference call or presentation 7-May-20 8:30pm GMT

Q1 2020 Syndax Pharmaceuticals Inc Earnings Call

Yahoo | June 10, 2020

Read More 'SNDX' Stories Here

SNDX Price Returns

1-mo 28.85%
3-mo 38.44%
6-mo 41.17%
1-year 215.01%
3-year 181.65%
5-year N/A
YTD 160.48%
2019 97.30%
2018 -49.20%
2017 22.18%
2016 N/A
2015 N/A

Continue Researching SNDX

Here are a few links from around the web to help you further your research on Syndax Pharmaceuticals Inc's stock as an investment opportunity:

Syndax Pharmaceuticals Inc (SNDX) Stock Price | Nasdaq
Syndax Pharmaceuticals Inc (SNDX) Stock Quote, History and News - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9828 seconds.